Strong Sun Care and Basic Product Exports
Securing Growth Momentum for Earnings Improvement in the Second Half

According to analysts in the securities market, Kolmar Korea is expected to accelerate its performance improvement in the second half of the year, driven by solid sun care orders and strong exports.


On August 4, according to IBK Investment & Securities, Researcher Cho Kyungjin stated the previous day, “Kolmar Korea is an Original Development Manufacturing (ODM) company with strengths in the production of high-margin sun care and basic care products. The company is expected to maintain its growth momentum, backed by robust exports from its domestic subsidiary, decreased seasonality in order volumes, and normalization of its U.S. subsidiary.” The investment opinion on Kolmar Korea was set to “Buy” with a target price of 150,000 won.

[Click eStock] "Kolmar Korea's Unrivaled Position in Sun Care Market... Target Price 150,000 Won" View original image

Q2 Operating Profit Forecast: 96.9 Billion Won… Up 32% Year-on-Year

Kolmar Korea’s consolidated sales for the second quarter are estimated to reach 826.9 billion won (up 13.2% year-on-year), with an operating profit of 96.9 billion won (up 32%).


The domestic subsidiary is expected to drive this earnings growth. This is due to increased sun care orders as the summer peak season begins and a rise in export volumes from existing customers. Sales of the domestic subsidiary are projected at 403.9 billion won (up 23.1% year-on-year), with operating profit forecast at 64.2 billion won (up 45.2%).


Researcher Cho explained, “Both the increase in orders from major clients and the greater share of production related to global brands are leading to margin expansion.” Global exports of high-growth indie brands such as Round Lab and Dr. Althea are concentrated at the domestic subsidiary, driving order growth.

Benefit from U.S. FDA Ingredient Approval… Anticipated Order Expansion

Changes in the U.S. regulatory environment are also favorable. Recently, the U.S. Food and Drug Administration (FDA) approved 'Bemotrizinol' as an ingredient for sunscreen—marking the first addition of a new ingredient since the late 1990s.


Researcher Cho noted, “The burden of having to separately develop products for the U.S. market has been removed, and domestic companies can now utilize their accumulated formulation technology as is.” As such, expansion of Kolmar Korea’s ODM sun care orders is anticipated. Since exports of cosmetics to the U.S. increased significantly in the first half, it is analyzed that new orders will gradually rise from the second half onward.


Pharmaceutical and health functional food manufacturing subsidiary HK Inno.N and cosmetic container manufacturing subsidiary Yonwoo are also acting as buffers for overall performance. HK Inno.N is expected to record sales of 274.1 billion won (up 4% year-on-year), helping to reduce volatility in the cosmetics sector. Yonwoo is projected to post sales of 69.2 billion won (down 2%), thereby narrowing the decline in profit.



Regarding the target price, Researcher Cho stated, “We applied a 20% premium to the global cosmetics ODM industry average price-to-earnings ratio of 16.8 times, reflecting Kolmar Korea’s unrivaled position in the sun care category, mitigation of seasonality, and improved visibility of earnings.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing